Zynex raises FY20 revenue view to $78M-$83M from $75M-$80M » 09:3204/0704/07/20
Consensus is for FY20…
Consensus is for FY20 revenue $72.38M. The Company is increasing its FY20 revenue estimate to between $78M-$83M from $75M-$80M. The updated revenue estimate is now approximately 72%-83% above last year's full year revenue of $45.5M. FY20 estimated adjusted EBITDA remains unchanged at $15.0M-$18.0M. The company said: "Similar to many companies we have seen the impact of the COVID-19 pandemic, not only on the availability of physicians to prescribe our products but also on navigating employee and supply chain issues. March orders were down 15% compared to the average number of orders in January and February 2020, which is a smaller decline than we had expected considering the nationwide impact of COVID-19. The numbers have since stabilized and remain constant through the last 3 weeks of March and the early days of April." The company added, "Our cash collections in the Q1 of this year were strong which adds to our confidence in the full year estimates. We continue to add sales reps and train our sales force. In the month of March, we added 32 sales reps and we still expect to reach our goal of filling all 400 territories throughout the US by November of this year."
Zynex raises Q1 revenue view to $14.9M-$15.4M from $14.0M-$14.5M » 09:2804/0704/07/20
Consensus is for Q1…
Consensus is for Q1 revenue $14.13M. Zynex reports Q1 orders were 126% above the number of orders in the Q1 of FY19 and 3% sequentially above the Q4 of FY9. In the Q4 of FY19, orders grew 129% year-over-year. Due to the solid increase in orders and strong collections the Company has updated its previous estimate for the first quarter of 2020 to between $14.9M-$15.4M compared to the previous estimate of between $14.0M-$14.5M. Q1 Adjusted EBITDA is now expected to come in between $2.8M-$3.3M up half a million from the previous estimate.
|Over a week ago|
Northland starts Zynex at Outperform on pain management potential » 07:5804/0104/01/20
Northland analyst James…
Northland analyst James Terwilliger initiated coverage of Zynex with an Outperform rating and $15 price target. Zynex participates in the pain management and rehabilitation market, which the company estimates is approximately $500M worldwide, Terwilliger tells investors in a research note. The analyst believes the pain management market is experiencing significant disruption due to the safety and legal issues surrounding the opioid epidemic and that Zynex will be able to capture additional share.
Zynex initiated with an Outperform at Northland » 07:4704/0104/01/20
Northland analyst James…
Northland analyst James Terwilliger initiated coverage of Zynex with an Outperform rating and $15 price target.
|Over a month ago|
Zynex price target raised to $15 from $13 at H.C. Wainwright » 09:1102/2802/28/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Yi Chen raised the firm's price target on Zynex to $15 from $13 and reiterates a Buy rating on the shares. The company reported 2019 sales growth of 43% and its 2020 guidance suggests even stronger growth at around 70%, Chen tells investors in a post-earnings research note.
Fly Intel: After Hours Movers » 19:1202/2702/27/20
SCOR, FTCH, ZYXI, SWN, ICAD, NPTN, AMC, TTD, NKTR, FTAI, WDAY, LYV, OPRX, SGMO, FTSV, BHVN, GDI, BIG, GPOR, BYND, RUN, CHRS, GKOS, AAOI, VMW, EB, AAXN, MYL, IQ, SPPI, DELL, CARA, ADSK, RIGL, PSTG, BBBY
UP AFTER EARNINGS:…
UP AFTER EARNINGS: comScore (SCOR) up 20.5%... Farfetch (FTCH) up 15.7%... Zynex (ZYXI) up 11.6%... Southwestern Energy (SWN) up 10.0%... iCAD (ICAD) up 10.0%... NeoPhotonics (NPTN) up 10.0%... AMC Entertainment (AMC) up 8.1%... Trade Desk (TTD) up 6.2%... Nektar Therapeutics (NKTR) up 5.9%...Fortress Transportation (FTAI) up 4.0%... Workday (WDAY) up 2.5%... Live Nation (LYV) up 2.2%... OptimizeRX (OPRX) up 2.1%. ALSO HIGHER: Sangamo (SGMO) up 39.5% after entering gene regulation therapy partnership with Biogen... Forty Seven (FTSV) up 29.1% after Bloomberg speculation about approach from Gilead... Biohaven (BHVN) up 6.0% after getting FDA approval for acute treatment of migraine... Garden Denver (GDI) up 2.1% after entering S&P500 index... DOWN AFTER EARNINGS: Big Lots (BIG) down 28.3%... Gulfport Energy (GPOR) down 11.1%... Beyond Meat (BYND) down 10.0%... Sunrun (RUN) down 10.0%... Coherus BioSciences (CHRS) down 8.8%... Glaukos (GKOS) down 7.5%... Applied Optoelectronics (AAOI) down 6.8%... VMWare (VMW) down 6.0%... Eventbrite (EB) down 5.4%... Axon Enterprise (AAXN) down 4.2%... Mylan (MYL) down 3.6%... iQIYI (IQ) down 3.4%... Spectrum Pharma (SPPI) down 3.3%... Dell Technologies (DELL) down 3.3%... Cara Therapeutics (CARA) down 3.2%... Autodesk (ADSK) down 2.6%... Rigel Pharma (RIGL) down 2.5%... Pure Storage (PSTG) down 2.1%. ALSO LOWER: Bed Bath Beyond (BBBY) down 2.0% after announcing strategic restructuring and job cuts. Movers as of 18:30ET.
Zynex sees FY20 revenue $75M-$80M, consensus $63.5M 16:1202/2702/27/20
Zynex sees Q1 revenue $14.0M-$14.5M , consensus $13.14M 16:1202/2702/27/20
Zynex reports Q4 EPS 9c, consensus 8c » 16:1102/2702/27/20
Reports Q4 revenue…
Reports Q4 revenue $14.2M, consensus $13.77M.
Zynex receives FDA clearance for blood volume monitor » 09:1302/2502/25/20
Zynex announced the U.S.…
Zynex announced the U.S. FDA granted 510(k) clearance for sale in the U.S. for the CM-1500 Blood Volume Monitor.